Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well carfilzomib works in treating patients with multiple
myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth.